我国医药制造业创新不足原因探究&#x02014;&#x02014;以江苏省为例

徐惟; 廖占力

doi:10.19546/j.issn.1674-3830.2022.8.023

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (8) : 113-117. DOI: 10.19546/j.issn.1674-3830.2022.8.023

医药经纬

我国医药制造业创新不足原因探究——以江苏省为例

徐惟¹, 廖占力²

作者信息 +

Research on the Causes of Insufficient Innovation in China's Pharmaceutical Manufacturing Industry——Taking Jiangsu Province as an Example

Author information +

文章历史 +

摘要

医药制造业是我国战略性发展的重点行业,近年来取得了较快发展,但也存在诸多问题,尤其表现为企业的创新能力不足。本文利用经典的智猪博弈模型,针对目前医药制造业以模仿创新为主的发展现状,剖析我国医药缺乏自主创新的客观原因,并提出提升医药制造业创新能力的相关建议。

Abstract

The pharmaceutical manufacturing industry is a key industry for China's strategic development. In recent years, it has achieved rapid development, but there are also many problems, especially the enterprises lack innovative ability. This paper uses the classic boxed pig game model to analyze the reasons of lacking independent innovation in Chinese medicine under the current situation that pharmaceutical manufacturing industry mainly focuses on imitation, and puts forward suggestions to enhance the innovation ability of pharmaceutical manufacturing industry.

导出引用

徐惟, 廖占力. 我国医药制造业创新不足原因探究——以江苏省为例[J]. 中国医疗保险. 2022, 0(8): 113-117 https://doi.org/10.19546/j.issn.1674-3830.2022.8.023

Research on the Causes of Insufficient Innovation in China's Pharmaceutical Manufacturing Industry——Taking Jiangsu Province as an Example[J]. China Health Insurance. 2022, 0(8): 113-117 https://doi.org/10.19546/j.issn.1674-3830.2022.8.023

中图分类号： F840.684 C913.7

参考文献

[1] 华夏时报.我国创新药在研品数量全球贡献率13.9%,已从第三梯队进入第二梯队[EB/OL].(2021-03-03).https://www.chinatimes.net.cn/article/104901.html.
[2] 中国政府网.“重大新药创制”科技重大专项收官[EB/OL].(2021-02-02)http://www.gov.cn/xinwen/2021-02/02/content_5584285.htm.
[3] 江苏统计局.2020江苏统计年鉴 [J].北京:我国统计出版社,2020.
[4] 伍琳,陈永法.我国创新药物研发能力的国际比较及成因分析[J].我国卫生政策研究,2017,8:23-28.
[5] 产业信息网. 2020年我国仿制药行业发展现状及行业发展规模分析预测[EB/OL].(2020-05-08). https://www.chyxx.com/industry/202005/860003.html.
[6] 国家统计局.2020中国高技术产业统计年鉴[J].北京:中国统计出版社,2020.